---
title: "Xizang Weixinkang Pharmaceutical: Net profit of 183 million yuan in the first half of 2025, a year-on-year increase of 11.82%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254773240.md"
description: "Xizang Weixinkang Pharmaceutical announced that in the first half of 2025, operating revenue was 586 million yuan, a year-on-year decrease of 7.43%. Net profit was 183 million yuan, a year-on-year increase of 11.82%"
datetime: "2025-08-27T09:31:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254773240.md)
  - [en](https://longbridge.com/en/news/254773240.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254773240.md)
generator: "portal-rs"
---

# Xizang Weixinkang Pharmaceutical: Net profit of 183 million yuan in the first half of 2025, a year-on-year increase of 11.82%

Xizang Weixinkang Pharmaceutical announced that in the first half of 2025, operating revenue was 586 million yuan, a year-on-year decrease of 7.43%. Net profit was 183 million yuan, a year-on-year increase of 11.82%

### Related Stocks

- [603676.CN](https://longbridge.com/en/quote/603676.CN.md)

## Related News & Research

- [US health agencies report 55 cases of E. coli and salmonella infections tied to alfalfa sprouts](https://longbridge.com/en/news/296645342.md)
- [Michaels launches omnichannel custom framing experience with Architectural Digest](https://longbridge.com/en/news/296643293.md)
- [Frozen blueberries recall categorized under FDA's highest Class I risk level](https://longbridge.com/en/news/296506599.md)
- [SandboxAQ introduces AQPotency for virtual drug screening](https://longbridge.com/en/news/296467103.md)
- [Hengrui Pharma launches RMB 1 billion-RMB 2 billion A-share buyback, caps price at RMB 81.78](https://longbridge.com/en/news/296368941.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**